drugset / Trial / NCT01808950
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiquimod | Small molecule | 60 mg | Topical |
| Subject | Resiquimod | Small molecule | 100 mg | Topical |